SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

The upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with a Nov. 22 target date, is driving discussion. Bulls see the amended filings upper-limb data, rare-disease policy discussions and launch-related hiring as encouraging, while skeptics cite the prior negative advisory-committee review and ongoing uncertainty about efficacy and the potential label.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a treatment for recurrent respiratory papillomatosis has renewed focus on competition for Precigens PAPZIMEOS. Traders debate whether the new entrant threatens Precigens first-mover commercial lead or whether the selloff overstates the risk, citing differences in approval status, clinical data and commercialization challenges.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA add-on reimbursement for DefenCath could decline after early 2027 has driven concern about pricing and sales. Traders are divided: some see the comments as a threat to DefenCaths economics, while others argue DaVitas outlook is preliminary and point to CMSs published estimate as a counterpoint.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention as shares reach a 52-week high ahead of anticipated Q3 earnings, with traders focused on BRIUMVIs sales growth and the upcoming subcutaneous formulation. Buyout talk and short-squeeze speculation are also prominent, but a potential acquisition remains unconfirmed; some traders instead attribute the rally to earnings expectations and the commercial story.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis ahead of the topline results. Traders are debating whether GPS improved survival versus the physicians-choice control arm: bulls expect a strong result, while bears question the trial assumptions and point to the share-price weakness despite the milestone.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq/tech selloff, amplified by Intels weak outlook, has focused discussion on whether heavy AI infrastructure spending will deliver adequate returns and whether the AI trade is overvalued. Traders are split between treating the decline as an oversold buying opportunity and warning that further losses may follow; concerns about persistent inflation and higher rates add pressure.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A broader market selloff, fueled by weak Amazon and Intel reactions and concerns over heavy AI spending, is weighing on DIA; rising oil prices and Iran-related supply fears add to inflation and rate-hike concerns. Traders largely discuss bearish positioning and puts, though some see the Dow as holding up better than technology-heavy indexes.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor stocks are selling off as weak Intel guidance and concerns about Amazons AI spending and cash flow revive doubts about whether the AI buildout will earn adequate returns. Traders are split between expecting further downside as the AI trade unwinds and treating the sectors sharp decline near major technical support as a potential dip-buying opportunity.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons quarterly results beat expectations, with Eylea HD and Sanofi collaboration revenue tied to Dupixent highlighted as key growth drivers. Traders welcomed the sharp rally and breakout, while some focused on whether newer drugs and pipeline programs can sustain growth.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadogs sharp selloff followed quarterly results that beat expectations and raised its annual outlook, but traders focused on guidance suggesting slower near-term growth. Debate centers on whether a major AI customers reported usage reduction signals broader consumption softness, with valuation concerns adding pressure while some investors view the decline as an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


j88proco

Uyen Lieu